Nationwide registry for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan

Nationwide registry for patients with pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors in Japan - Nationwide NET registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016380

Enrollment

1800

Registered

2015-01-31

Start date

2015-01-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic, gastroenteral, bronchopulmonary, and thymic neuroendocrine tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient with pathological diagnosis as defined below after Jan 1st 2012 who are receiving follow-up examination after institutional IRB/IEC approval a) NET G1/G2, NEC, or MANEC as pancreatic or gastroenteral neuroendocrine tumors b) TC (Typical carcinoid), AC (Atypical carcinoid), LCNEC (Large cell neuroendocrine carcinoma) as bronchopulmonary neuroendocrine tumors c) Any type of thymic neuroendocrine tumors 2) Patient with pancreatic, gastroenteral, bronchopulmonary, and thymic NET 3) Written informed consent (written informed consent from their parents or their legal representative who may represent their intent and interest will be needed when subjects are under 20 years old)

Exclusion criteria

Exclusion criteria: 1) Patient with pathologically diagnosed small cell lung cancer (SCLC) as bronchopulmonary neuroendocrine tumors 2) Patients previously enrolled into this study 3) Patients regarded as ineligible for other reason by the investigator.

Design outcomes

Primary

Measure	Time frame
Prognosis of the disease	—

Countries

Japan

Contacts

Public ContactToshihiko Masui

Japan Neuroendocrine Tumor Society Secretariat

jnets-office@umin.ac.jp075-751-3242

Outcome results